Kadimastem: Funding, Investors & Team (Sep 2026)
Kadimastem is a company that focuses on developing and commercializing stem cell-based treatments for diabetes and neurodegenerative disorders. Their technology allows them to differentiate stem cells into insulin-producing beta cells and various neural cells. They are currently working on therapeutic programs for diabetes and ALS, using differentiated stem cells to potentially implant into patients. The company partners with pharmaceutical companies to screen potential drug compounds on their stem cell-derived cells in order to develop safe drugs. Kadimastem is located in Nes Ziona, Israel.
Kadimastem has raised $5.2M across 2 funding rounds on record, the most recent an undisclosed round of $170k announced in Jul 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kadimastem Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Kadimastem Funding Rounds
Kadimastem raised $5.0M in a Post-IPO Equity announced in Oct 2021.
3.8 years later, an undisclosed round of $170k was announced in Jul 2025.
Kadimastem Founders and Leadership Team
Contact details for the Kadimastem team: 1 of 2 have an email address on file.
Start 14-day free trial →Kadimastem Funding Compared to Other Biotechnology Startups
Kadimastem's latest round of $170k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kadimastem in Biotechnology and Ness Ziona
Companies Similar to Kadimastem
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
Kadimastem Funding FAQs
What does Kadimastem do?
Kadimastem is a company that focuses on developing and commercializing stem cell-based treatments for diabetes and neurodegenerative disorders. Their technology allows them to differentiate stem cells into insulin-producing beta cells and various neural cells. They are currently working on therapeutic programs for diabetes and ALS, using differentiated stem cells to potentially implant into patients. The company partners with pharmaceutical companies to screen potential drug compounds on their stem cell-derived cells in order to develop safe drugs. Kadimastem is located in Nes Ziona, Israel.
How much funding has Kadimastem raised?
Kadimastem has raised $5.2M across 2 rounds on record. The most recent is an undisclosed round of $170k announced in Jul 2025.
When did Kadimastem last raise funding?
Kadimastem's most recent funding round on record is an undisclosed round of $170k, announced in Jul 2025.
Who founded Kadimastem?
FundedIQ lists Rami Epstein (Founder) at Kadimastem.
Who is the CEO of Kadimastem?
Asaf Shiloni is listed as CEO at Kadimastem.
Where is Kadimastem headquartered?
Kadimastem is based in Ness Ziona, Hamerkaz, Israel.
How many employees does Kadimastem have?
Kadimastem is in the 11-50 employee band.
How does Kadimastem's funding compare to other Biotechnology startups?
Kadimastem's latest round of $170k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Kadimastem Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kadimastem is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.